Protagonist Therapeutics. PTGX 6.82 1.08 (13.67%). NASDAQUpdated Mar 16, 2020 8:34 PM. 1,397. Watchers. Watch. Filter by: Real-Time. 0 New Post. Protagonist Therapeutics, Inc. Common Stock (PTGX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. PTGX: Get the latest Protagonist Therapeutics stock price and detailed information including PTGX news, historical charts and realtime prices. Analyzing Protagonist Therapeutics (NASDAQ:PTGX) stock? View PTGX's stock price, price target, earnings, financials, forecast, insider trades, news, and SEC  Get breaking news and analysis on Protagonist Therapeutics, Inc. (PTGX) stock, price quote and chart, trading and investing tools.

PTGX: Get the latest Protagonist Therapeutics stock price and detailed information including PTGX news, historical charts and realtime prices.

Find the latest Protagonist Therapeutics, Inc. (PTGX) stock quote, history, news and other vital information to help you with your stock trading and investing. PTGX | Complete Protagonist Therapeutics Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview. Protagonist Therapeutics. PTGX 6.82 1.08 (13.67%). NASDAQUpdated Mar 16, 2020 8:34 PM. 1,397. Watchers. Watch. Filter by: Real-Time. 0 New Post.

investment & stock information. Get the latest Protagonist Therapeutics, Inc. PTGX detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.

Stock analysis for Protagonist Therapeutics Inc (PTGX:NASDAQ GM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Find real-time PTGX - Protagonist Therapeutics Inc stock quotes, company profile, news and forecasts from CNN Business. PTGX stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, Ikarian Capital LLC, Jacobs Levy Equity Management Inc., Renaissance Technologies LLC, Prudential Financial Inc., Nuveen Asset Management LLC, Spark Investment Management LLC, and State Street Corp. Company insiders that have bought Protagonist Therapeutics stock in the last two years include Bryan Giraudo, Donald A Kalkofen, Harold E Selick, and Suneel Gupta. Real-time trade and investing ideas on Protagonist Therapeutics PTGX from the largest community of traders and investors. ST Invest is a wholly owned subsidiary of StockTwits, Inc. Investing in securities products involves risk, including possible loss of principal. Stock analysis for Protagonist Therapeutics Inc (PTGX:NASDAQ GM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.

Stock quote for Protagonist Therapeutics, Inc. Common Stock Common Stock (PTGX) with real-time last sale and extended hours stock prices, company news, charts, and research at Nasdaq.

Stock quote for Protagonist Therapeutics, Inc. Common Stock Common Stock (PTGX) with real-time last sale and extended hours stock prices, company news, charts, and research at Nasdaq. Protagonist Therapeutics, Inc. Common Stock (PTGX) Q1 2019 Earnings Call Transcript Motley Fool Transcribing | May 15, 2019 PTGX earnings call for the period ending March 31, 2019. Protagonist Therapeutics, Inc. Common Stock (PTGX) Real-time Stock Quotes - Nasdaq offers real-time quotes & market activity data for US and global markets. Protagonist Therapeutics, Inc. Common Stock (PTGX) Q1 2019 Earnings Call Transcript Motley Fool May-14-19 07:00AM Oral Alpha-4-Beta-7 Integrin Antagonist PN-943 Demonstrates Superior Dose-Related Target Engagement Activity to PTG-100 in Single Ascending Dose Phase 1 Study PR Newswire Discover historical prices for PTGX stock on Yahoo Finance. View daily, weekly or monthly format back to when Protagonist Therapeutics, Inc. stock was issued. Stock quote and company snapshot for PROTAGONIST THERAPEUTICS INC (PTGX), including profile, stock chart, recent news and events, analyst opinions, and research reports. PTGX's NASDAQ Last Sale (NLS) "Last Sale" is the price at which a stock last traded during regular market hours. NLS Volume "Volume" is the number of shares of the stock traded on the listing

Analyzing Protagonist Therapeutics (NASDAQ:PTGX) stock? View PTGX's stock price, price target, earnings, financials, forecast, insider trades, news, and SEC 

IPO Status Public Stock Symbol NASDAQ:PTGX Company Type For Profit. Website www.protagonist-inc.com LinkedIn View on LinkedIn Contact Email  3 Dec 2019 Protagonist Therapeutics Inc. stock (NASDAQ:PTGX) nosedived 47% on Tuesday after the company released preliminary results from its phase  專注於發現及開發以胜肽為基礎的新藥Protagonist Therapeutics, Inc.(PTGX.US) 成立 stock PTGX image. Protagonist Therapeutics. 〈PTGX〉. 基本資料 · 行情 報價  Initiated Coverage by Barclays Capital (Ranked 25th) to Overweight $PTGX # PTGX $PTGX - David Y. Liu Sells 3,500 Shares of Protagonist Therapeutics Inc   5 Dec 2019 The stock rallied to close the day with gains of 72.92%. This came a day after it announced early results for its ongoing phase 2 study for PTG-300  8 May 2019 and biopharma Protagonist Therapeutics Inc (NASDAQ:PTGX). Below, we will dive into what is moving the shares of WKHS, PM, and PTGX.

• 10 year chart of gold prices
• singapore consumer price index forecast
• daily bid rates
• advanced diploma in offshore rig oil and gas safety engineering
• 10 year treasury rate history cnbc
• oaudrhd